688193 Shanghai Rendu Biotechnology
- 31.55
- -0.21-0.66%
Shanghai Rendu Biotechnology News
Express News | Rendu Biotech: Net profit decreased by 64.6% to 8.2593 million yuan in 2023, plans to pay 10 to 2 yuan
Rendu Biotech (688193.SH): Net profit of 3.7039 million yuan in the first quarter
On April 29, Ge Longhui (688193.SH) released its report for the first quarter of 2024, achieving operating income of 44.8151 million yuan, an increase of 15.60% over the previous year; net profit attributable to shareholders of listed companies was 3.7039 million yuan, and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1.0853 million yuan, with basic earnings per share of 0.09 yuan.
Rendu Biotech (688193.SH): Cumulative repurchase of 1.00% of the company's shares
Gelonghui, April 11, 丨 Rendu Biotech (688193.SH) announced that as of April 10, 2024, the company had repurchased 400,049 shares of the company's shares through centralized bidding transactions, accounting for 1.00% of the company's total share capital of 40,000,000 shares, an increase of 0.02% compared with the previous disclosure. The highest price of the repurchase transaction was 30.00 yuan/share, and the lowest price was 28.47 yuan/share. The total amount of capital paid was RMB 11,938,945.00 (excluding stamp duty and transactions) transaction costs such as commissions).
Rendu Biotech (688193.SH): Accumulated repurchases of 392,200 shares
Gelonghui, April 1, 丨 Rendu Biotech (688193.SH) announced that as of March 31, 2024, the company had repurchased 392,167 shares of the company's shares through centralized bidding transactions, accounting for 0.98% of the company's total share capital. The highest price of the repurchase transaction was 30.00 yuan/share, the lowest price was 28.47 yuan/share, and the total capital paid was RMB 11,702,640.53 (excluding transaction fees such as stamp duty and transaction fees).
Rendu Biotech (688193.SH): The ban on 500,000 restricted shares was lifted on April 1
Gelonghui March 20 丨 Rendu Biotech (688193.SH) announced that the total number of shares in circulation in the company's current stock listing is 500,000 shares. The stock listing and circulation date is April 1, 2024 (postponed to the next trading day since March 30, 2024 is a non-trading day).
Rendu Biotech (688193.SH): A total of 202,300 shares have been repurchased as of February 29
Gelonghui, March 1, 丨 Rendu Biotech (688193.SH) announced that as of February 29, 2024, the company had repurchased a total of 202,341 shares of the company's shares through centralized bidding transactions, accounting for 0.5059% of the company's total share capital. The highest price of the repurchase transaction was 30.00 yuan/share, the lowest price was 28.47 yuan/share, and the total capital paid was RMB 6,027,229.31 (excluding transaction fees such as stamp duty and transaction fees).
Rendu Biotech (688193.SH) performance report: 2023 net profit of 3.182,200 yuan, a year-on-year decrease of 86.36%
On February 27, Ge Longhui Biotech (688193.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 165 million yuan, a year-on-year decrease of 45.86%, and realized net profit attributable to owners of the parent company of 3.182,200 yuan, a year-on-year decrease of 86.36%; realized net profit attributable to the owner of the parent company after deducting non-recurring gains and losses of 125.903 million yuan, a year-on-year decrease of 354.89%.
Rendu Biotech (688193.SH): Initial repurchase of 26,500 shares
On February 22, 2024, Gelonghui Biotech (688193.SH) announced that on February 22, 2024, the company repurchased 26,463 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0662% of the company's total share capital. The highest price of the repurchase transaction was 30.00 yuan/share, the lowest price was 29.28 yuan/share, and the total capital commission paid was RMB 790,345.29 (excluding transaction fees such as stamp duty and transaction fees).
Rendu Biotech (688193.SH): Plans to repurchase the company's shares for 25 million yuan to 50 million yuan
On February 18, Gelonghui Biotech (688193.SH) announced that the company plans to buy back some of the company's issued RMB common stock (A shares) through centralized bidding transactions, with a total repurchase capital of not less than RMB 25 million and no more than RMB 50 million. The repurchase price is no more than 53.31 yuan/share.
Express News | Rendu Biotech: Chairman proposes to buy back the company's shares for 25 million yuan to 50 million yuan
Rendu Biotech (688193.SH) New Product Hepatitis C Virus Nucleic Acid Test Kit (RNA Capture Probe Method) Obtains Product Registration Certificate
Gelonghui, February 4, 丨 Rendu Biology (688193.SH) announced that the company's new product hepatitis C virus nucleic acid test kit (RNA capture probe method) has obtained a product registration certificate, registration category III. The above products can quantitatively detect hepatitis C virus (HCV) RNA in human serum samples and are used to evaluate the response and treatment effects of antiviral treatment. They are new products in the company's blood-borne infectious disease series; previously, quantitative testing products for hepatitis B RNA and AIDS in this series of products have also been certified on the market. The acquisition of the medical device registration certificate mentioned above has further enriched the company's product categories and helped enhance the company's external health
Jindu Biotech (688193.SH): Pre-cut net profit by 90% to 85% in 2023
Gelonghui, January 30丨Rendu Biotech (688193.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, the company expects to achieve net profit attributable to owners of the parent company in 2023 of 2.3 million yuan to 3.4 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will decrease by 21.03 to 19.93 million yuan, a year-on-year decrease of 90% to 85%. Net profit attributable to owners of the parent company in 2023, after deducting non-recurring profit and loss, is expected to be -13.47 million yuan to -12.37 million yuan, which will decrease compared with the same period last year (statutory disclosure data)
[BT Financial Report Instantaneous Analysis] Rendo Biotech's 2023 Quarterly Report: Fluctuations in performance coexist with growth in R&D investment
Rendo Biotech (stock code: 688193) is a high-tech enterprise focusing on the field of RNA molecular diagnosis. With its unique RNA real-time fluorescence thermostatic amplification detection (SAT) patented technology platform, it provides effective solutions for accurate diagnosis and personalized treatment of pathogens in various fields. The company's business covers molecular diagnostic reagents, instrumentation and third-party testing services. It has developed five series of nearly 20 products and has been recognized by many well-known institutions. As of the third quarter of 2023, Rendu Biotech has 27 approved medical device products, including 14 Class III medical devices
Rendu Biotech (688193.SH): The company's current reproductive health series products use non-invasive urine tests
On December 5, Glonghui, on the investor interactive platform, some investors asked Rendo Biotech (688193.SH), “Recently, I have paid a lot of attention to SAT-RNA testing technology. The advantages are obvious. I have a technical question that I would like to ask for advice on a technical question. What is the principle behind the fact that the urine test results promoted by your company are more consistent with the test results of other parts? For example, for men, are the results of testing for pathogens in urine highly consistent with those using prostate fluid? So can urine test results be used in place of prostate fluid tests?” The company said that the company currently uses none of its reproductive health products
Rendu Biotech (688193.SH): Net loss of 8.34 million yuan in the first three quarters
On October 30, Gelonghui (688193.SH) announced its third quarter report. Operating income was 117 million yuan, a year-on-year decrease of 51.23%, net loss of 8.34 million yuan, net loss of 8.34 million yuan, net loss of 14.42 million yuan, and basic earnings per share of -0.21 yuan.
Rendu Biotech (688193.SH) granted 782,600 restricted shares at a grant price of 38 yuan/share
Rendu Biotech (688193.SH) announced that on September 20, 2023, the company spent 38.00 yuan/share...
Rendu Biotech (688193.SH) plans to grant 782,600 restricted shares at a grant price of 38 yuan/share
According to the Zhitong Finance App, Rendu Biotech (688193.SH) disclosed the 2023 Restricted Stock Incentive Plan (draft). The company plans to grant 782.64 million restricted shares to incentive recipients (86 people in total) at a price of 38.00 yuan/share. According to reports, this incentive plan is valid for no more than 60 months from the date the restricted shares are granted until the date when all restricted shares granted to the incentive target expire in ownership or abolition.
Rendu Biotech (688193.SH) released semi-annual results, with a net loss of 10.19 million yuan, a year-on-year shift from profit to loss
According to the Zhitong Finance App, Rendu Biotech (688193.SH) disclosed the 2023 semi-annual report. The company achieved revenue of 8.03 million yuan, a year-on-year decrease of 52.83%; net profit loss of 10.19 million yuan, from profit to loss; deducting non-net profit loss of 14.56 million yuan, from profit to loss; basic earnings per share -0.25 yuan. During the reporting period, the company's traditional reagent product business achieved significant growth, but it has yet to make up for the adverse effects of the sharp decline in the reagent and testing service business related to epidemic prevention and control, resulting in a 52.83% drop in total revenue. Furthermore, in order to accelerate research and development, the company
Rendu Biotech (688193.SH) plans to launch a restricted stock incentive plan for 782.64 million shares
According to the Zhitong Finance App, Rendu Biotech (688193.SH) disclosed the 2023 Restricted Stock Incentive Plan (draft). The number of restricted shares to be granted to 86 incentive recipients was 782.64 million shares, accounting for about 1.96% of the company's total share capital when the draft incentive plan was announced. There were no reserved grants, and the grant price was 38 yuan per share.
Shanghai Rendu Biotechnology Gets Certificate for Registration of HIV Kit
Shanghai Rendu Biotechnology (SHA:688193) received a medical device registration certificate for its human immunodeficiency virus type I nucleic acid assay kit. The certificate is valid until June 19,
Analysis
Price Target
No Data
